Eisbach Bio and the federal CNATM Cluster for Nucleic Acid Therapies awarded funding to shape Germany’s R&D future
- deepak1536
- 29. Apr.
- 3 Min. Lesezeit
Munich, 29.04.2026 — The research consortium CNATM has secured its second round of funding in the German Clusters4Future program, commissioned by the Federal Ministry for Research, Technology and Space (BMFTR). As part of this pioneering translational initiative, Eisbach Bio will be developing therapeutic drugs that target cancer-driving nucleic acid regulators, supporting 𝗖𝗡𝗔𝗧𝗠’s research goals and subject focus on targeting nucleic acids.
This award supports our mission to push the boundaries of drug development by trapping the activated state of the molecular machines that reorganize the genome to promote cancer.
The CNATM network aims to develop new nucleic acid-based drugs and next-generation vaccines in areas of high unmet clinical need. Recent discoveries in the field of mRNA vaccines, but also in the field of chemical biology, synthetic lethality, and nucleic acid therapies, now give hope that nucleic acids and the machines that regulate nucleic acids have therapeutic potential as new “weapons” in mediating anti-viral, anti-cancer and immune modulation responses. CNATM brings together leading academic and industrial partners. Together, they are developing highly innovative therapeutics in nucleic acid chemistry. Alongside existing partners, such as the pioneering ADC company Tubulis, Eisbach is committed to supporting the network for an additional three years during this second period.
Specifically, Eisbach will continue its intensive R&D collaboration with leading partners, including:
• Ludwig-Maximilians-Universität München, München
• Tubulis GmbH, Planegg
• Coriolis Pharma Research GmbH, Planegg
About Eisbach Bio GmbH Eisbach Bio GmbH is a LMU spin off established in January 2019 on the Großhadern-Martinsried campus. Eisbach leverages the innovative therapeutic concept of synthetic lethality in tumor cells by developing small molecule drugs that hit the molecular vulnerability of our drug targets. In particular, Eisbach develops safe therapies that selectively target the activated state of our machines for the personalized therapy of cancer in genetically defined patient groups, including for indications that currently have no or few therapeutic options. Genomics has revealed tumor-specific genes that cancer cells critically depend on. By targeting both genetic and molecular vulnerabilities in cancer cells, Eisbach’s drugs hit the Achilles heel of tumors, effectively eliminating cancer cells with minimal side effects. Eisbach has developed a proprietary screening and development platform that traps the activated states of our targets, identifying allosteric inhibitors of these tumor-essential molecular machines.
EIsbach’s mission is to push the boundaries of drug development by trapping the activated state of the molecular machines that promote cancer.
About the BMBF’s Future Clusters Initiative: The German federal Clusters4Future initiative seeks to bring innovations to market. To ensure that Germany remains in the top group of innovation leaders, the BMBF launched an ambitious program to establish several regional R&D clusters that catalyze the existing research cooperation between leading academic institutions and industry. The fourteen future clusters in total are Germany’s innovation networks of the future. Their aim is to find suitable solutions for the major challenges of our time. The topics are as diverse as the winners’ concepts: neuromorphic hardware for autonomous systems, personalized cell and gene therapy processes, sustainable marine research, quantum technology, new approaches to drug discovery and development, as well as hydrogen fuel technologies. To this end, universities, research institutions, companies, social and other relevant players in the regions have joined forces, sharing exclusive knowledge with each other and pooling their expertise into joint R&D activities.
More information:
Eisbach Bio GmbH: www.eisbach.bio Email: info@eisbach.bio
Cluster4Future: https://www.clusters4future.de